The global Targeted Protein Degradation Market, valued at US$0.01 billion in 2024, stood at US$0.48 billion in 2025 and is ...

Arvinas, Inc. (NASDAQ:ARVN) is among the best US stocks under $10 to invest in. XTX Topco Ltd has increased its stake in ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alkermes (ALKS – Research Report), Staar Surgical (STAA – Research Report) and Arvinas Holdin ...

Arvinas Inc. (NASDAQ:ARVN) is one of the best small cap stocks with biggest upside potential. On August 8, Arvinas, in ...

Study participants were randomly assigned to receive either oral vepdegestrant (n=313) or intramuscular fulvestrant (n=311). The primary endpoint was progression free survival (PFS) among all patients ...

The FDA accepts a new drug application for vepdegestrant, a promising oral PROTAC developed by Arvinas and Pfizer, signaling ...

US FDA accepts Arvinas’ NDA for vepdegestrant to treat ESR1m, ER+/HER2- advanced breast cancer: New Haven, Connecticut Monday, August 11, 2025, 17:00 Hrs [IST] Arvinas, Inc., a ...

Arvinas, in collaboration with Pfizer, has announced new drug application (NDA) acceptance for vepdegestrant from the US Food ...

Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or ...

Explore Arvinas's Fair Values from the Community and select yours There's been a notable change in appetite for Arvinas, Inc. (NASDAQ:ARVN) shares in the week since its quarterly report, with the ...

Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced ...